United States: FDA Holds Public Hearing On Manufacturer Communication Of Scientific And Medical Information

On November 9 and 10, 2016, FDA held a public hearing to obtain input on manufacturer communications involving unapproved uses of approved or cleared medical products (i.e., "off-label" uses). The hearing was moderated by Leslie Kux (Associate Commissioner for Policy, Office of the Commissioner) and included numerous high-ranking FDA officials as panelists, including Commissioner Robert Califf.1 Nearly sixty speakers, including members of the biopharmaceutical and medical device industries, health care professionals, patient and public health advocates, payers, and academics, testified at the hearing.

Ropes & Gray partner Kellie Combs (Washington, D.C.) spoke on behalf of the Medical Information Working Group ("MIWG"), urging the FDA to establish clear, constitutionally appropriate policies that permit biopharmaceutical and medical device manufacturers to share truthful and non-misleading scientific and medical information about their products with health care professionals and payers.

This Alert summarizes several key aspects of the hearing and describes its potential significance for regulated industry.

Overview of the Public Hearing

As discussed in a previous Ropes & Gray alert, FDA's Federal Register notice requested stakeholder comments about off-label communications and asked more than two dozen questions about whether and in what way FDA should change its regulations. Notably, while courts have held that truthful, non-misleading off-label speech is protected by the First Amendment, and that the Fifth Amendment requires government agencies such as FDA to issue clear and narrowly tailored rules when regulating speech, the Federal Register notice made only a single, passing reference to constitutional developments.

In his opening remarks, Dr. Califf spoke about the rationale for the agency's speech restrictions, emphasizing the importance of premarket review of new uses of approved products and describing several commonly cited examples of the potential harms that may result from off-label communications (e.g., the thalidomide case). He also acknowledged that FDA-approved or-cleared labeling does not contain all clinically relevant information, and he asked whether health care professionals currently faced challenges in accessing off-label information.

More than half of the speakers advocated for broader allowances for manufacturer communications, arguing that the provision of clear pathways for manufacturers to communicate truthful, non-misleading, clinically relevant off-label information is critical to the public health and consistent with constitutional requirements. Many of the speakers, however, favored tighter FDA restrictions on manufacturer speech, though they generally grounded their arguments in the potential dangers associated with lawful off-label use rather than off-label communications by manufacturers.

Presentations in Favor of Greater Flexibility and Clarity in FDA's Regulatory Scheme

Speakers in favor of broader dissemination of truthful and non-misleading scientific and medical information asserted that manufacturers are often able to provide valuable and unique insights to both payers and healthcare professionals, and that FDA's current framework sharply limits manufacturers from sharing information even when consistent with the approved or cleared indication. Speakers also explained that, in addition to the public health benefits associated with greater flexibility to engage in off-label communications, the First and Fifth Amendments prohibit the government from restricting truthful and non-misleading speech unless the rules are clear and are narrowly drawn to advance a compelling government interest. Health care professionals argued that they benefit from receiving up-to-date information that, in many cases, only manufacturers are able to provide, and payers explained the significant advantages early pipeline communications with manufacturers would have on formulary planning and insurance rates. Numerous patient groups contended that off-label communications are necessary in the context of rare diseases such as lupus and pediatric cancer, where on-label treatments are either ineffective or unavailable.

Presentations in Favor of the Status Quo or Enhanced FDA Regulation

Several speakers, including academics and physicians, also advocated on behalf of FDA's current regulatory regime, and some argued that FDA should impose broader restrictions, limiting all forms of manufacturer communication about unapproved uses. These speakers asserted that off-label communications are invariably detrimental to the public health, expressing concerns that modifications to FDA's regulatory framework would increase off-label prescribing and that manufacturers would share low-quality data or misleading information. Speakers also contested the impact of the recent constitutional case law, arguing that FDA's public health mission should take precedence over speech arguments raised by industry or other advocates for greater flexibility in the agency's regulatory regime.

FDA will accept written comments from interested stakeholders until January 9, 2017.

Implications of the Public Hearing

The FDA panelists were noticeably engaged during the public hearing, and most speakers received multiple questions. It was evident from the questions that the agency is cognizant of the public health value of off-label information, particularly with respect to serious or life-threatening conditions and in therapeutic areas where on-label treatments are limited. However, it was also clear that FDA remains uncomfortable with significantly relaxing long-standing agency rules and is grappling with the potential impact that constitutional case law has on its highly restrictive regulatory framework.

The ultimate impact of the public hearing is difficult to predict. When FDA granted two citizen petitions submitted by the members of the MIWG in 2014, it stated that it was engaged in a comprehensive review of its regulations and policies governing manufacturer speech and promised to issue four relevant guidance documents by the end of that year. FDA has still not issued those guidance documents or otherwise taken any meaningful action to clarify or modify its regulatory scheme.


1 The full panel included Rachel E. Sherman (Deputy Commissioner for Medical Products and Tobacco), Kristin Davis (Senior Policy Advisor, Office of Policy, Office of the Commissioner), Karen E. Schifter (Senior Counsel, Office of the Chief Counsel, Office of the Commissioner), Diane Maloney (Associate Director for Policy, Center for Biologics Evaluation Research), Thomas Abrams (Director, Office of Prescription Drug Promotion, Center for Drug Evaluation and Research), Lauren Silvis (Deputy Director for Policy, Center for Devices and Radiological Health), and Dorothy McAdams (Supervisory Veterinary Medical Officer, Office of Surveillance and Compliance, Center for Veterinary Medicine).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.